ArticlePediatric nephrology (Berlin, Germany)2004
Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 57 citations in OpenAlex.
- Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.Pediatric nephrology (Berlin, Germany) · 2011Trial
- Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors.Pediatric nephrology (Berlin, Germany) · 2006Trial
- Dynamic evolution of kidney function in patients with STEC-hemolytic uremic syndrome followed for more than 15 years: unexpected changes.Pediatric nephrology (Berlin, Germany) · 2025Article
- Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2023Article
- Review
- Review
- Hemolytic uremic syndrome.Seminars in immunopathology · 2014Review
- Treatment strategies to prevent renal damage in hypertensive children.Current hypertension reports · 2014Review
- Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2013Article
- Chapter 6: Blood pressure management in children with CKD ND.Kidney international supplements · 2012Article
- Educational paper: Progression in chronic kidney disease and prevention strategies.European journal of pediatrics · 2012Review
- Hemolytic uremic syndrome: late renal injury and changing incidence-a single centre experience in Canada.Scientifica · 2012Article
- Clinical practice: proteinuria.European journal of pediatrics · 2011Review
- Clinical practice. Today's understanding of the haemolytic uraemic syndrome.European journal of pediatrics · 2010Review
- Chronic Kidney Disease in Children: An Indian Perspective.Medical journal, Armed Forces India · 2009Article
- Therapeutic strategies to slow chronic kidney disease progression.Pediatric nephrology (Berlin, Germany) · 2008Review
- Progression of chronic renal failure in children with dysplastic kidneys.Pediatric nephrology (Berlin, Germany) · 2007Article
- Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Five patients with severe hemolytic uremic syndrome (HUS) were followed for 10-18 years. Because of proteinuria, arterial hypertension, and reduced glomerular filtration rates, they received either captopril (n=2) or enalapril (n=3), or both (n=1) for 8-15 years. Blood pressure was normalized and proteinuria reduced in all; glomerular filtration improved in three patients and fell moderately in two. Four of the five patients have reached adult age with body weight and height, blood pressure, and serum creatinine levels within the normal range. At the last evaluation, median proteinuria was 220 mg/24 h (range 0-310) and glomerular filtration rate 56 ml/min per 1.73 m(2)(range 40-127). This long-term study indicates a renoprotective effect of angiotensin-converting enzyme inhibitors in patients with sequelae after HUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.